Barclays PLC increased its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report) by 1.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 550,186 shares of the company’s stock after acquiring an additional 7,287 shares during the period. Barclays PLC’s holdings in Vir Biotechnology were worth $4,121,000 at the end of the most recent reporting period.
Other institutional investors have also recently bought and sold shares of the company. Louisiana State Employees Retirement System boosted its stake in shares of Vir Biotechnology by 2.8% during the 2nd quarter. Louisiana State Employees Retirement System now owns 43,800 shares of the company’s stock valued at $390,000 after buying an additional 1,200 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Vir Biotechnology by 0.8% during the second quarter. Bank of New York Mellon Corp now owns 813,288 shares of the company’s stock worth $7,238,000 after acquiring an additional 6,359 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Vir Biotechnology by 15.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 24,647 shares of the company’s stock valued at $219,000 after purchasing an additional 3,215 shares during the last quarter. Innealta Capital LLC purchased a new position in Vir Biotechnology in the second quarter valued at about $32,000. Finally, Rhumbline Advisers increased its position in Vir Biotechnology by 4.3% in the 2nd quarter. Rhumbline Advisers now owns 238,504 shares of the company’s stock worth $2,123,000 after purchasing an additional 9,817 shares during the last quarter. 65.32% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several brokerages have recently issued reports on VIR. Barclays reduced their price target on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Monday, November 4th. HC Wainwright reissued a “buy” rating and issued a $110.00 target price on shares of Vir Biotechnology in a research report on Wednesday, November 20th. Finally, Needham & Company LLC restated a “buy” rating and set a $19.00 price target on shares of Vir Biotechnology in a report on Wednesday, November 20th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $36.40.
Vir Biotechnology Stock Down 0.4 %
NASDAQ:VIR opened at $7.34 on Monday. The company’s 50 day moving average is $8.02 and its 200-day moving average is $8.53. Vir Biotechnology, Inc. has a 12 month low of $6.56 and a 12 month high of $13.09. The firm has a market cap of $1.01 billion, a price-to-earnings ratio of -1.87 and a beta of 0.49.
Vir Biotechnology (NASDAQ:VIR – Get Free Report) last announced its earnings results on Thursday, October 31st. The company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($1.05) by ($0.51). Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The firm had revenue of $2.38 million during the quarter, compared to the consensus estimate of $5.54 million. During the same quarter last year, the business earned ($1.22) EPS. The business’s revenue was down 9.8% compared to the same quarter last year. Research analysts predict that Vir Biotechnology, Inc. will post -3.36 EPS for the current fiscal year.
Vir Biotechnology Company Profile
Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).
Read More
- Five stocks we like better than Vir Biotechnology
- 3 Tickers Leading a Meme Stock Revival
- XPO Stock Gains Momentum as U.S. Trade Outlook Evolves
- How to invest in marijuana stocks in 7 steps
- CarMax Gets in Gear: Is Now the Time to Buy?
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Qubit Combat: 2 Stocks Battle for Quantum Supremacy
Want to see what other hedge funds are holding VIR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report).
Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.